Asahi Kasei Pharma to Discontinue Development of Teribone Transdermal Patch Formulation in Japan

Asahi Kasei Pharma announced on January 31 that it has decided to halt the development of the transdermal patch formulation of Teribone (teriparatide), a human parathyroid hormone preparation, in Japan. Asahi Kasei Pharma has been developing the drug utilizing the...read more